New ACIP Panel Votes to Recommend Clesrovimab, Second Antibody to Prevent RSV in Infants

The seven newly appointed members of ACIP voted 5-to-2 to recommend Enflonsia, the second long-acting monoclonal ...

JUNE 26, 2025

Infant RSV Hospitalization Rates Dropped Significantly After Antibody, Vaccine Prevention Introduced

RSV-associated hospitalization in infants fell sharply during the first virus season after the introduction of ...

JUNE 5, 2025

FDA Requires GBS Warning for RSV Vaccines

The FDA required and approved safety labeling changes to the prescribing information for RSV vaccines to include a ...

JANUARY 13, 2025

FDA Grants New Indication for Abrysvo for At-Risk Adults From 18 to 59

The FDA granted a new indication for Pizer’s Abrysvo RSV vaccine for younger adults whose chronic condition ...

OCTOBER 23, 2024

Changes to RSV Vaccine Recommendations Aim to Help Those Most at Risk

The ACIP recently changed its recommendations for respiratory syncytial virus vaccination suggesting that everyone ...

OCTOBER 12, 2024

RSV Vaccine Safety Findings Similar to Clinical Trial Results

GSB continues to be the most common serious adverse event from RSV vaccinations, but the effect is relatively rare. ...

JULY 11, 2024

ACIP Updates RSV Vaccine Recommendations

After receiving real-world data, ACIP updated its recommendations about shared decision making and other issues ...

JUNE 26, 2024

FDA Grants Expanded Indication for GSK’s Arexvy

The FDA granted a new indication for GSK’s Arexvy adjuvanted respiratory syncytial virus vaccine to prevent ...

JUNE 13, 2024

Vaccination Against U.S. Respiratory Diseases Remains Low

Vaccination against COVID-19, influenza and RSV remains low in the United States, and is particularly low for ...

JANUARY 26, 2024